ClinicalTrials.gg
CompletedNCT03704909EpiEphUpdated Mar 13, 2019

Manging Post Spinal Hypotension During Elective Cesarean Section

A Phase 4 interventional study of Adrenaline and Ephedrine in Hypotension, sponsored by Ben marzouk Sofiene. Completed at 1 site in Tunisia. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-13.

Sponsored by Ben marzouk Sofiene · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Spinal anesthesia is the gold standard technique for elective cesarean section. It helps to avoid risks regarding airway management and provides effective neuraxial postoperative analgesia, enabling quicker maternal recovery. Cesarean section normally require an anesthetic block at T4 level. So that maternal hypotension is reported to occur in up to 80%. This can result in significant morbidity for both the mother and fetus.The purpose of this study is to determine if epinephrine is as effective and safe compared to ephedrine for maintaining arterial blood pressure during elective cesarean section under spinal anesthesia. All participants will receive spinal anesthesia with a local anesthetic and sufentanil. This study plans to enroll 140 healthy pregnant women. Patients will be randomly assigned according to a computer generated system to be in one of two groups.

Read the detailed description

Its a prospective double-blinded controlled trial. All participants gave a written informed consent. One hundred and twenty healthy women, ASA II, with singleton pregnancies at term scheduled for elective cesarean section under spinal anesthesia are targeted for the study. They are randomized to receive either epinephrine or ephedrine. Upon arrival in the operating room, parturient was placed in the supine position with 15° left lateral tilt with routine monitoring (HR, non-invasive BP, pulse oximetry, electrocardiography). Baseline BP and HR were computed as the mean of three consecutive BP and HR readings respectively at 1-minute intervals. Study participants will receive a standard spinal anesthetic consisting of 0.5% hyperbaric bupivacaine (2 mL) plus sufentanil (5 µg) at L3-4 vertebral interspace.

Group A (for adrenaline group): received a prophylactic intravenous (i.v) bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, were given if maternal BP decreased more than 20% from the baseline value.

Group E (for ephedrine group): received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, were given if maternal BP decreased more than 20% from the baseline value. Once the spinal injection was performed a rapid intravenous (i.v.) coload with 15mL/Kg of isotonic saline solution was started through a 16 G i.v. cannula (by turning the i.v. infusion to maximum and using a pressure bag inflated to 150 mmHg). A prophylactic bolus of vasopressor was administered at the end of spinal injection. After performing anesthesia, the parturient was immediately replaced in the supine position with a 15° left lateral table tilt until delivery of the infant. Prior to surgical incision, the spinal sensory level will be tested to the bilateral T6-T4 dermatomal level. Sensory block level was checked by cold-hot test and the Modified Bromage Scale was used for the assessment of motor block. The surgery was allowed when the sensory block level reached D4. Both the patient and the researcher's assistant (who will collect data) will be blinded as to the administered Epinephrine or Ephedrine bolus. Supplemental oxygen will be given only when the pulse oximeter reading decreased below 95%. After delivery, 5 IU of oxytocin diluted in 20 ml of isotonic saline solution were slowly injected over 1 minute. Then an i.v infusion was given (10 IU/500ml of isotonic saline solution at a flow rate of 28 drops/min).

Heart rate (beats/min), systolic, mean and diastolic blood pressure (mmHg) will be recorded every 1 min after spinal injection until the end of surgery. The incidence of hypotension (defined as a reduction in SBP of >20% from baseline determined just before the administration of spinal anesthesia) will be recorded. Reactive hypertension (defined as a rise of SBP >20% of baseline) will also be recorded. Bradycardia (defined as HR \<50 beats/min) will be recorded. Tachycardia (defined as a HR >140 beats/min) will also be recorded. Umbilical blood samples will be obtained by clamping it on both sides and a gas analysis will be performed to determine fetal pH, HCO3-, base excess and lactates. Furthermore, Apgar scores at 1 and 5 minutes after delivery will be recorded by the attending pediatrician, who will be unaware of the vasopressor used. The study will end when cesarean section is completed and the patient is transferred to the post-operative care unit.

02

Conditions studied

  • Hypotension

Browse trials for

Keywords

  • Epinephrine, Ephedrine, cesarean section, spinal anesthesia
03

In context

Hypotension

885 studies on the registry are indexed under Hypotension; 195 are open to participants now.

This study's enrollment of 143 is above the median of 87 across 590 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Ben marzouk Sofiene is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 and \<35 Kg/m2
  • full term parturients with singleton pregnancy
  • scheduled of elective cesarean section under spinal anesthesia

Non-inclusion criteria:

  • Patient refusal.
  • ASA > II
  • Preexisting or pregnancy-induced hypertension
  • The use of cardiac medication or medication for BP control.
  • Cardiovascular or cerebrovascular disease.
  • Multiple pregnancy.
  • Suspicion of abnormal placentation.
  • Known fetal abnormalities or fetal distress.
  • CS under general anesthesia.
  • Active labor.
  • Emergency.
  • Allergy to any of the medications used in the study.

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability that is not in relationship with SA (occurrence of a surgical per-operative complication e.g. bleeding by placental insertion abnormality or a uterine atony).
  • An abnormal extension of the anesthetic block defined as a sensory block level > D4.
  • SA failure.
  • The need to convert to general anesthesia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Active comparator
    Group Adrenaline: Group A

    All parturients received a prophylactic i.v bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.

    Drug: Adrenaline

  • Active comparator
    Group Ephedrine: Group E

    All parturients received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.E

    Drug: Ephedrine

Interventions

  • i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg

    Also known as: epinehrine

  • i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg

06

What researchers measure

Primary outcomes

  1. delta SBP (D)

    difference between baseline and the lowest systolic blood pressure.

    Time frame: at the end of intrathecal injection until delivery

  2. delta MBP (D)

    difference between baseline and the lowest mean blood pressure.

    Time frame: at the end of intrathecal injection until delivery

Secondary outcomes

  1. delta SBP (S)

    difference between baseline and the lowest systolic blood pressure.

    Time frame: at the end of intrathecal injection until the end of surgery

  2. delta MBP (S)

    difference between baseline and the lowest mean blood pressure.

    Time frame: at the end of intrathecal injection until the end of surgery

  3. time to onset of first post spinal hypotension episode

    first episode of hypotension after spinal anesthesia induction

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  4. Incidence of post spinal hypotension

    a decrease of SBP \>20% of baseline

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  5. Vasopressor consumption

    cumulative dose of vasopressor consumption

    Time frame: from the end of intrathecal injection until delivery.

  6. Vasopressor consumption

    cumulative dose of vasopressor consumption

    Time frame: from the end of intrathecal injection until the end of surgery.

  7. number of rescue boluses

    number of rescue boluses before and after delivery

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  8. incidence of hypertension

    a rise of SBP \>20% of baseline

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  9. tachycardia

    heart rate\>140 beats/min

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  10. incidence of arrythmia

    incidence of arrhythmic events

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  11. incidence of bradycardia

    heart rate (HR) \< 50 beats/min

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  12. use of atropine

    cumulative dose, if needed

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  13. incidence of nausea and vomiting

    Measure will be done according to a simple scale: 0= no nausea and vomiting; 1= nausea or vomiting

    Time frame: At time of surgery (right after spinal anesthesia until end of surgery)

  14. foetal gas analysis: pH, Lactates, HCO3-, BE

    fetal cord blood analysis will be done immediately after delivery

    Time frame: At time of birth

  15. APGAR score

    range from 0 to 10,incorporates five elements: respiratory effort, heart rate, reflex irritability, muscle tone, and color A score of 0 to 3 indicates a severely depressed neonate, whereas a score of 7 to 10 is considered normal.

    Time frame: at 1 and 5 minutes after birth

07

Study locations

1 site
  • Tunis maternity and neonatology center,
    Tunis, 1007, Tunisia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Dec 2018, 3 months.

Of 60 non-industry phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 3 months is below that.

Counting every sponsor, half of 61 studies reached it within 12 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2018
First posted
Oct 15, 2018
StartActual
Sep 1, 2018
Primary completionActual
Dec 31, 2018
CompletionActual
Dec 31, 2018
Last update
Mar 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03704909
Lead sponsor
Ben marzouk Sofiene
Responsible party
Ben marzouk Sofiene (clinical associate professor, University Tunis El Manar) — Sponsor-investigator
First posted
Oct 15, 2018
Start date
Sep 1, 2018
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018
Last update
Mar 13, 2019

Study contacts

HAYEN MAGHREBIG, PROFESSOR
study chair · UNIVERSITY OF TUNIS EL MANAR

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epinephrine · Ephedrine

Start the discussion